Related Experiment Video
Updated: Oct 18, 2025
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.3K
BTK Inhibitors in Chronic Lymphocytic Leukemia
Sameh Gaballa1,2, Javier Pinilla-Ibarz3
1Department of Malignant Hematology, Lymphoma Section, Moffitt Cancer Center, Tampa, FL, USA. sameh.gaballa@moffitt.org.
Current Hematologic Malignancy Reports
|October 2, 2021
Summary
Bruton tyrosine kinase (BTK) inhibitors have transformed chronic lymphocytic leukemia (CLL) treatment. New BTK inhibitors and combinations offer improved options for both new and relapsed CLL patients.
Area of Science:
- Oncology
- Hematology
Background:
- The treatment of chronic lymphocytic leukemia (CLL) has evolved significantly with targeted therapies.
- Physicians now have multiple effective treatment options for CLL patients.
Purpose of the Study:
- To review the role of Bruton tyrosine kinase (BTK) inhibitors in treating chronic lymphocytic leukemia (CLL).
- To discuss BTK inhibitors for treatment-naïve and relapsed/refractory CLL.
- To cover recent approvals and clinical trial data for BTK inhibitors in CLL.
Main Methods:
- Review of recent approvals of BTK inhibitors.
- Analysis of reported and ongoing clinical trial data.
- Examination of the evolving treatment landscape for CLL.
Main Results:
- Ibrutinib, a first-generation BTK inhibitor, has shifted CLL management paradigms.
- Second-generation BTK inhibitors (acalabrutinib, zanubrutinib) offer improved selectivity.
- Acalabrutinib is now approved for CLL treatment.
Conclusions:
- BTK inhibitors are crucial in managing CLL, both in treatment-naïve and relapsed/refractory settings.
- Future research focuses on BTK inhibitor combinations and next-generation agents for resistant mutations.
- The CLL treatment landscape is rapidly changing due to novel BTK agents and combination therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
02:34Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259